Form 4 for ATRA Atara Biotherapeutics, Inc.
Accepted 2021-12-03 00:00:00 ET · period of report 2021-12-01 · accession 0001567619-21-021583 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-12-03 | 2021-12-01 | ATRA | Dupont Jakob | EVP, Head of R, D | M - OptEx | $9.58 | +5,000 | 95.6K | +6% | +$47.9K |
| D | 2021-12-03 | 2021-12-01 | ATRA | Dupont Jakob | EVP, Head of R, D | S - Sale+OE | $17.94 | -5,000 | 90.6K | -5% | -$89.7K |
| D | 2021-12-03 | 2021-12-01 | ATRA | Dupont Jakob | EVP, Head of R, D | M - OptEx | $0.00 | -5,000 | 267.5K | -2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-12-01 | M | A | 5,000 | $9.58 | 95,594 | D | — | — | |
| 2 | Common | Common Stock | 2021-12-01 | S | D | 5,000 | $17.94 | 90,594 | D | — | — | (F2) The price in Column 4 is a weighted average sale price. The prices actually received ranged from $17.78 to $18.135. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 3 | Derivative | Employee Stock Option (Right to Buy) | 2021-12-01 | M | D | 5,000 | $0.00 | 267,500 | D | $9.58 · — to 2030-05-13 | 5,000 Common Stock | (F3) 25% of the shares subject to the option vested on May 14, 2021 and the remaining shares vest in equal monthly installments over the following 36 months, subject to the reporting person's continuous service. |